CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFRs antagonists(Fibroblast growth factor receptors antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesOther Diseases+ [6]

Active Indication

Locally Advanced Lung Non-Small Cell Carcinomametastatic non-small cell lung cancerRecurrent Non-Small Cell Lung Cancer+ [21]

Inactive Indication

Acute Erythroblastic LeukemiaAcute Promyelocytic LeukemiaAdenocarcinoma of large intestine+ [60]

Originator Organization

Boehringer Ingelheim International GmbH

Active Organization

Boehringer Ingelheim GmbHBoehringer Ingelheim Pharma GmbH & Co., KGBoehringer Ingelheim Pty Ltd.

+ [15]

Inactive Organization

Meilaipu (Beijing) Pharmaceutical Research Co., Ltd.

Boehringer Ingelheim Ltd.Boehringer Ingelheim España SA

License Organization

Grand Pharmaceutical (China) Co., Ltd.

Santen Pharmaceutical Co., Ltd.

Mount Sinai Medical Center of Florida, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (15 Oct 2014),

Idiopathic Pulmonary Fibrosis

RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Special Review Project (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (China)

Structure/Sequence

Molecular FormulaC33H39N5O7S

InChIKeyMMMVNAGRWOJNMW-FJBFXRHMSA-N

CAS Registry656247-18-6

272

Clinical Trials associated with Nintedanib esylate

NCT07335562

/ RecruitingPhase 3

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

Start Date29 Aug 2026

Sponsor / Collaborator

Juno Therapeutics, Inc.

[+1]

NCT07679893

/ Not yet recruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Followed by an Open-Label Extension

This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1/FVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.

Start Date30 Jun 2026

Sponsor / Collaborator

MannKind Corp.

JPRN-jRCT2033260131

/ Not yet recruitingPhase 3

Start Date14 May 2026

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Nintedanib esylate

100 Translational Medicine associated with Nintedanib esylate

100 Patents (Medical) associated with Nintedanib esylate

2,429

Literatures (Medical) associated with Nintedanib esylate

01 Sep 2026·Biofabrication

Targeting the YAP-mediated stromal signaling unlocks chemoresistance in a human organoid fibrosis model

Article

Author: Xiong, Duoer ; Chen, Wei ; Chen, You ; Zheng, Qihang ; Li, Meiqi ; Liu, Jie ; Zhang, Changhua

Abstract:

The fibrotic stroma drives tumor progression and impairs therapy, but existing models fail to capture its dual barrier and signaling roles, limiting mechanistic understanding and therapeutic development. To address this, we established a patient-derived fibrotic tumor model that recapitulates key pathophysiological features: extracellular matrix remodeling, substantial tissue stiffening (12-fold increase), and pro-malignant transcriptomic reprogramming. This model demonstrated microenvironment-mediated chemoresistance, increasing the area under the dose‐response curve by 1.3-fold and suppressing oxaliplatin-induced apoptosis. Although stiffening delayed drug penetration, barrier disruption did not restore sensitivity. Instead, stiffness inactivated the Hippo pathway, activating YAP as the key chemoprotection driver. YAP inhibition restored drug sensitivity without altering stiffness, revealing a targetable biochemical mechanism independent of the physical barrier. Using this insight, we designed a sequential regimen in which nintedanib preconditioning precedes chemotherapy, achieving near-complete tumor eradication (<5% tumor viability). This work provides a physiological model of stromal biology and a mechanism-guided strategy to overcome microenvironment-mediated chemoresistance.

01 Sep 2026·EXPERIMENTAL EYE RESEARCH

Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights

Article

Author: Aykut, Aslan ; Şahin, Özlem ; Midi, Ahmet ; Ertaş, Büşra ; Vurgun, Elif Bağatur ; Çetin, Burcu ; Sevik, Mehmet Orkun

BACKGROUND:

To evaluate the efficacy and safety of intravitreal injection of the multityrosine kinase inhibitor nintedanib (NTB) in a mouse model of proliferative vitreoretinopathy (PVR) induced by dispase.

METHODS:

Fifty-two male C57BL/6 mice received intravitreal injections in the right eye and were divided into four groups: PVR, PVR + NTB, NTB-only, and vehicle. Uninjected contralateral eyes served as a healthy-control group. The PVR and PVR + NTB groups were compared based on clinical and histopathological PVR grading. Immunohistochemistry, ELISA, RT-PCR, and Western blot analyses were used to evaluate and compare markers of inflammation, fibrogenesis, and epithelial-mesenchymal transition between PVR, PVR + NTB, and healthy-control groups. Potential retinal toxicity was assessed using electroretinography and histopathology in the NTB-only and vehicle groups.

RESULTS:

Clinical PVR grades were significantly lower in the PVR + NTB group (0.65 ± 0.93) than in the PVR group (2.70 ± 1.75) (p < 0.001). Histopathological grading was also significantly lower in the PVR + NTB group (1.62 ± 0.91) compared with the PVR group (3.87 ± 1.24) (p = 0.002). Compared with the PVR group, IL-6, PDGF, TGF-β, and TNF-α levels, as well as acta-2, col1a1, and fn-1 mRNA expression were significantly lower in the PVR + NTB group. Phosphorylated-PDGFR-α levels were also reduced, whereas PDGFR-α protein expression remained unchanged. No signs of retinal toxicity were observed in electroretinography or histopathology.

CONCLUSIONS:

In this mouse PVR model, intravitreal NTB reduced clinical, histopathological, and biochemical manifestations of PVR without detectable toxicity. Intravitreal NTB may represent a promising therapeutic option for the management of PVR.

01 Sep 2026·HEART & LUNG

Reassessment of risk profiles through weight and BMI changes in idiopathic pulmonary fibrosis

Article

Author: Özyürek, Berna Akıncı ; Kısmet, Gözde Kalbaran ; Demirci, Nilgün Yılmaz ; Akkurt, Esma Sevil ; Gülen, Şule Taş ; Uçar, Hatice Arzu ; Uzer, Fatih ; Yazıcı, Onur ; Süleymanova, Samira ; Coşkun, Funda ; Hanta, İsmail ; Dikiş, Özlem Şengören ; Deniz, Pelin Pınar ; Okutan, Oğuzhan ; Günlüoğlu, Gülşah ; Sarıbaş, Ertan ; Tapan, Utku ; Bozkus, Fulsen ; Keskin, Olgun ; Dolmuş, Tunahan

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease in which weight loss and low BMI have emerged as adverse prognostic indicators. However, longitudinal data on early weight change-particularly in patients receiving antifibrotic therapy-remain limited. This study examined the relationship between first-year weight change and clinical outcomes in a multicenter IPF cohort from Türkiye.

METHODS:

This retrospective study analyzed 428 patients diagnosed with IPF between 2019 and 2024 across 12 centers. Weight at diagnosis and one year, clinical characteristics, antifibrotic treatment, pulmonary function tests, 6MWD, and survival outcomes were evaluated. Annual weight change was categorized as no loss, <5% loss, or ≥5% loss; significant weight loss was defined as ≥5%.

RESULTS:

Among 428 patients (mean age 68.3 ± 8.0 years; 82% male), 78.5% experienced significant weight loss during follow-up. At the end of the first year, baseline BMI and the prevalence of diabetes mellitus decreased progressively with increasing weight loss, with the lowest values observed in patients with ≥5% weight loss (p = 0.018 and p = 0.023, respectively). In parallel, greater weight loss at the end of the first year was associated with worse pulmonary function, reflected by declining FVC (L and % predicted) and DLCO (% predicted), while rates of dietitian evaluation increased markedly, reaching the highest level in the ≥5% weight loss group (all p ≤ 0.036). During follow-up, patients with ≥5% weight loss lost an average of 6.20 kg, while those without loss gained 0.22 kg (p < 0.001). Greater annual FVC decline occurred in both weight-loss groups (p = 0.018 and p = 0.005), whereas DLco decline was similar across groups. Antifibrotic use-especially nintedanib-was more frequent among those with ≥5% loss (p = 0.010). Weight loss was not associated with mortality or hospitalization, but correlated with greater functional deterioration. Age and baseline BMI independently predicted weight change.

CONCLUSIONS:

Early weight loss is common in IPF and is associated with accelerated functional decline, independent of antifibrotic therapy. Routine weight monitoring may provide additional prognostic value and supports incorporating body composition into IPF risk stratification.

267

News (Medical) associated with Nintedanib esylate

18 Jun 2026

·www.globenewswire.com

New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses.Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses. "I expect that nerandomilast will offer a transformative survival benefit for patients with either IPF or PPF,” said Toby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles. “In clinical practice, we believe that slowing FVC decline is one important precursor to improving survival in people with IPF and PPF. Data from the FIBRONEER™ trials, plus the survival modeling, are showing us improvements that are truly meaningful, suggesting nerandomilast may have an effect on survival beyond that mediated by reducing decline in FVC." In patients with IPF, it is estimated that nerandomilast 18 mg monotherapy could more than double median survival to 9.1 years, extending it from 3.7 years with no therapy. For those receiving standard background therapy with nintedanib, adding nerandomilast 18 mg is predicted to increase median survival from 4.6 years to 6.0 years.1 In patients with PPF, it is predicted that nerandomilast 18 mg monotherapy could extend median survival to 7.2 years compared to 3.9 years with no therapy. When added to background nintedanib, predicted median survival is extended from 3.4 years to 4.4 years.2 "IPF and PPF are devastating, life-threatening diseases that ruthlessly steal time from patients. Historically, burdensome side effects have forced many to abandon therapy limiting the potential for a sustained treatment effect,” said Dr. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim. “Nerandomilast represents a meaningful step forward. By offering an effective and safe therapy that patients can actually tolerate, it supports sustained, long-term treatment. If patients are able to stay on therapy longer, nerandomilast may have the potential to translate its predicted survival benefit into what really matters: more precious time with family and loved ones.” In FIBRONEER™-IPF and FIBRONEER™-ILD nerandomilast met its primary endpoint, demonstrating slowed lung function decline compared to placebo as measured by the absolute change in Forced Vital Capacity (FVC) from baseline to week 52 in IPF and PPF, respectively. While the key secondary endpoint* was not met in either FIBRONEER™-trial, in a pooled analysis of FIBRONEER™-trials, a 59% nominally significant reduction in the risk of death was observed in participants treated with nerandomilast 18 mg as monotherapy compared with placebo.3 *The key secondary endpoint was time to first acute IPF/ILD exacerbation, first hospitalization for respiratory cause, or death over the duration of trial About the survival modeling analysis The survival benefits were estimated using a statistical model based on data from the FIBRONEER™-IPF and FIBRONEER™-ILD trials. Researchers used a standard method (Weibull distribution modeling) to estimate long-term survival outcomes over a 30-year period, assuming consistent treatment effects and discontinuation rates similar to those seen during the respective trials.1,2 It is important to note that these figures represent modeled projections, not observed patient outcomes from the clinical trials. Data from the open-label extension of the FIBRONEER™ trials, FIBRONEER™-ON, and real-world evidence will provide further evidence into the long-term effect of nerandomilast. About nerandomilast JASCAYD® (nerandomilast) is an oral preferential PDE4B inhibitor with antifibrotic, immunomodulatory and vascular effects approved in the US, China, the UAE, and Japan for the treatment of adults with IPF and adults with PPF. Regulatory submissions for nerandomilast in IPF and PPF are also under review in the European Union - having received a positive CHMP opinion in May 2026 - the UK, and other countries, with additional approvals anticipated in 2026. Boehringer Ingelheim is also exploring the potential of nerandomilast in two rheumatic diseases: systemic sclerosis (SSc) and myositis (IIM). About IPF and PPF Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are both conditions with irreversible build-up of scar tissue in the lungs, affecting the lungs’ ability to take in and transfer oxygen into the bloodstream.4,5,6 Signs and symptoms of IPF and PPF include a persistent dry cough and shortness of breath on exertion.6,7 In IPF, the root cause of pulmonary fibrosis is not known.4 The disease primarily affects people over the age of 50 and affects more men than women.8 In PPF, the scarring of the lungs may be linked to an existing condition (e.g. rheumatoid arthritis or systemic sclerosis), which causes inflammation of the lung tissue repeatedly and leads to fibrosis. PPF can also result from exposure to inhaled substances (e.g. asbestos or mold) or be due to an unknown cause (idiopathic) and worsens despite treatment of the condition.5 Together, IPF and PPF may affect up to 9.2 million people worldwide.9,10 Approximately half of people with IPF or PPF die within 5 years of diagnosis11,12,13 – a higher mortality rate than many cancers.14,15 Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. References Pimple et al. Predicting long-term survival benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF). (Poster presented at ATS 2026)Maher et al. Predicting long-term survival benefit of nerandomilast in patients with progressive pulmonary fibrosis (PPF). (Poster presented at EULAR 2026Oldham J et al. (Pooled analysis from the FIBRONEER IPF and FIBRONEER ILD trials- ERS 2025) 2025;392(22):2203-2214.Upagupta C, et al. Eur Respir Rev. 2018;27:180033.Kondoh Y, Inoue Y. Adv Ther. 2025;42(7):2988–3001.van Cleemput, J, et al. Adv Ther. 2019;36, 298–317.Kondoh Y, et al. Respir Investig. 2021;59(6):709-740.Wang J, et al. MedComm (2020). 2024;5(10):e744.Podolanczuk AJ, et al. Eur Respir J. 2023;61(4)2200957.Cottin V, et al. Front Med (Lausanne). 2022;9:799912.　Zheng Q et al. ERJ Open Res. 2022;8(1):00591-2021.Cen Z, et al. Ann Med. 2024;56(1):2406439.Nasser M, et al. Respir Res. 2021.22 :162.Siegel RL, et al. CA Cancer J Clin. 2024;74(1):12–49.Vancheri C, et al. Eur Respir J. 2010;35(3):496–504.

Clinical ResultPhase 3Drug Approval

17 Jun 2026

·www.globenewswire.com

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Company expects to report topline 12-month clinical results in the second half of 2027BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. “PPF is a serious and progressively debilitating condition that can lead to a steady decline in lung function, increasing symptom burden, and reduced quality of life,” said Tim Whelan, MD, Professor of Medicine at the Medical University of South Carolina and investigator in the Phase 2b MIST trial. “Even with today's treatments, the prognosis remains poor, with median survival of just three to five years after diagnosis. We urgently need options that can meaningfully alter the course of this disease and improve outcomes for patients. Completing target enrollment in this trial is an exciting milestone as we assess the therapeutic potential of AP01.” MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. “We are energized to have completed target enrollment in MIST,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “Strong enthusiasm from investigators and patients enabled us to reach this milestone ahead of schedule, underscoring the demand for new treatment options in PPF. Based on data from the ATLAS Phase 1b trial and our ongoing open-label extension study, we believe AP01’s tolerability profile may enable patients to remain on treatment longer. We expect MIST to help inform the full impact of AP01 on preserving lung function and improving quality of life for people living with PPF, and we look forward to reporting topline data in the second half of 2027.” About AP01 AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid® Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF. For more information, please visit www.clinicaltrials.gov. About Avalyn PharmaAvalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, implied and express statements about Avalyn’s beliefs and expectations regarding the possibility that additional patients may be enrolled in the Phase 2b MIST trial; the timing of topline 12-month clinical results in the Phase 2b MIST clinical trial of AP01 in the second half of 2027; the interpretation and significance of the Phase 2b MIST trial and Phase 1b ATLAS clinical data; and the therapeutic potential of its product candidates. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that earlier results may not be indicative of future results; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions; risks related to our ability to protect and maintain our intellectual property position or relationships with third-parties; the initiation, timing, progress and results of our current and future research and development programs, preclinical studies and clinical trials; our ability to successfully complete our clinical trials; our ability to advance any product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates; the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates; and risks related to needs for additional financing. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Avalyn’s current and future filings with the Securities and Exchange Commission, including those described from time to time under the caption “Risk Factors.” In addition, any forward-looking statements represent Avalyn’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Avalyn explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor and Media Contact:Cassie Saitow, Avalyn Pharma Inc.Sr. Director, IR and Corporate Communicationsir@avalynpharma.com

Phase 2Clinical Result

15 Jun 2026

·www.einpresswire.com

Idiopathic Pulmonary Fibrosis Market Size Projected to Reach USD 6.16 Billion by 2030 at a 7.0% CAGR, Says AMR

Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth PORTLAND, OR, UNITED STATES, June 15, 2026 / EINPresswire.com / -- Allied Market Research published a report, titled, " Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global Idiopathic Pulmonary Fibrosis Market Size was Valued at USD 3.12 billion in 2020 and is Projected to Garner USD 6.16 billion by 2030, registering a CAGR of 7.0% from 2021 to 2030. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market. ๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐๐๐๐ญ๐จ๐ซ๐ฌ ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐๐ข๐จ๐ฉ๐๐ญ๐ก๐ข๐ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐๐ซ๐ฒ ๐๐ข๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ? Increase in incidences of cancer worldwide, favorable reimbursement policies provided by manufacturers & insurance providers, and rise in cigarette smoking drive the growth of the global idiopathic pulmonary fibrosis market. However, the unavailability of the proper treatment options restrains the market growth. On the other hand, rise in number of pipeline drugs and untapped potential in developing countries present new opportunities in the coming years. ๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/4407 ๐๐จ๐ฉ ๐๐๐ข๐จ๐ฉ๐๐ญ๐ก๐ข๐ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐๐ซ๐ฒ ๐๐ข๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ โข AstraZeneca PLC โข Bristol-Myers Squibb Company โข Boehringer Ingelheim โข GNI Group Ltd โข F. Hoffmann-La Roche Ltd. (Genentech, Inc.,) โข Shiongi co Ltd โข Mission Therapeutics โข Biogen, Inc. โข Galapagos NV โข FibroGen, Inc. ๐๐๐ข๐จ๐ฉ๐๐ญ๐ก๐ข๐ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐๐ซ๐ฒ ๐๐ข๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง ๐๐๐ง ๐๐ ๐๐จ๐ง๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ฌ๐๐ฏ๐๐ซ๐๐ฅ ๐๐๐๐ญ๐จ๐ซ๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ : Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue its leadership status during the forecast period. Moreover, this segment is projected to manifest the highest CAGR of 7.2% from 2021 to 2030. This is due to rise in adoption of pirfenidone drugs such as Esbriet and Pirespa across the world. The research also analyzes the nintedanib segment. Based on distribution channel, the retail pharmacies segment accounted for the highest share in 2020, contributing to nearly half of the global idiopathic pulmonary fibrosis market, and is estimated to continue its lead position during the forecast period. This is attributed to rapid increase in rate of idiopathic pulmonary fibrosis among the geriatric population, technological advancements, and lifestyle changes worldwide. However, the online providers segment is expected to portray the largest CAGR of 8.5% from 2021 to 2030. This is due to offers and discounts offered by providers and the availability of different types of drugs under a single platform. Based on region, North America contributed to the highest market share in 2020, holding more than two-fifths of the global idiopathic pulmonary fibrosis market, and is projected to continue its lead in terms of revenue by 2030. This is attributed to high expenditure on R&D activities, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to manifest the fastest CAGR of 8.9% during the forecast period, owing to improvement in R&D facilities and rapidly developing economic conditions. ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/purchase-enquiry/4407 Our Market Research Solution Provides You Answer to Below Mentioned Question: โข Which are the driving factors responsible for the growth of market? โข Which are the roadblock factors of this market? โข What are the new opportunities, by which market will grow in coming years? โข What are the trends of this market? โข Which are main factors responsible for new product launch? โข How big is the global & regional market in terms of revenue, sales and production? โข How far will the market grow in forecast period in terms of revenue, sales and production? โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022? โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030? โข Which region has more opportunities? By Region Outlook โข North America (U.S., Canada, Mexico) โข Europe (Germany, France, UK, Italy, Spain, Rest of Europe) โข Asia-Pacific (Japan, China, India, Rest of Asia-Pacific) โข LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA) Contact Details: David Correa USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 help@alliedmarketresearch.com About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. David Correa Allied Market Research + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Nintedanib esylate

External Link

KEGG	Wiki	ATC	Drug Bank
D10396 D10481	Nintedanib esylate	L01XE31	DB09079

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Australia	Boehringer Ingelheim Pty Ltd.	01 Sep 2015
metastatic non-small cell lung cancer	Australia	Boehringer Ingelheim Pty Ltd.	01 Sep 2015
Recurrent Non-Small Cell Lung Cancer	Australia	Boehringer Ingelheim Pty Ltd.	01 Sep 2015
Interstitial lung disease due to systemic disease	European Union	Boehringer Ingelheim International GmbH	14 Jan 2015
Interstitial lung disease due to systemic disease	Iceland	Boehringer Ingelheim International GmbH	14 Jan 2015
Interstitial lung disease due to systemic disease	Liechtenstein	Boehringer Ingelheim International GmbH	14 Jan 2015
Interstitial lung disease due to systemic disease	Norway	Boehringer Ingelheim International GmbH	14 Jan 2015
Progressive fibrotic interstitial lung disease	European Union	Boehringer Ingelheim International GmbH	14 Jan 2015
Progressive fibrotic interstitial lung disease	Iceland	Boehringer Ingelheim International GmbH	14 Jan 2015
Progressive fibrotic interstitial lung disease	Liechtenstein	Boehringer Ingelheim International GmbH	14 Jan 2015
Progressive fibrotic interstitial lung disease	Norway	Boehringer Ingelheim International GmbH	14 Jan 2015
Adenocarcinoma of Lung	European Union	Boehringer Ingelheim International GmbH	21 Nov 2014
Adenocarcinoma of Lung	Iceland	Boehringer Ingelheim International GmbH	21 Nov 2014
Adenocarcinoma of Lung	Liechtenstein	Boehringer Ingelheim International GmbH	21 Nov 2014
Adenocarcinoma of Lung	Norway	Boehringer Ingelheim International GmbH	21 Nov 2014
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	15 Oct 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic interstitial lung disease	NDA/BLA	European Union	Accord Healthcare SL	22 Feb 2024
Lung Diseases, Interstitial	NDA/BLA	United States	Boehringer Ingelheim GmbH	25 Jul 2023
Pterygium	Phase 3	United States	Cloudbreak Therapeutics LLC	30 Jun 2022
Pterygium	Phase 3	China	Cloudbreak Therapeutics LLC	30 Jun 2022
Pterygium	Phase 3	Australia	Cloudbreak Therapeutics LLC	30 Jun 2022
Pterygium	Phase 3	India	Cloudbreak Therapeutics LLC	30 Jun 2022
Pterygium	Phase 3	New Zealand	Cloudbreak Therapeutics LLC	30 Jun 2022
Scleroderma	Phase 3	United States	Boehringer Ingelheim International GmbH	05 Dec 2017
Scleroderma	Phase 3	Japan	Boehringer Ingelheim International GmbH	05 Dec 2017
Scleroderma	Phase 3	Argentina	Boehringer Ingelheim International GmbH	05 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2026	Not Applicable	Lung Diseases, Interstitial	1,037	biologic-treated RA	yyzxllgxzr(evkqzvjsqr) = When available, baseline PFTs showed a median FVC of 99% (60-157) predicted, FEV1 90% (41-145), DLCO 71% (40-98), and values declined at first follow-up to FVC 86% (52-193), FEV1 88% (53-182), DLCO 65% (44-94). suzzfckoat (pkqounxnfb ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	51	Mycophenolate mofetil + Rituximab	suczrhljua(iqpqxfjhuq) = vexslldjnl pbbjjfclth (abwtzjyepp ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	51	Mycophenolate mofetil + Rituximab + Nintedanib	suczrhljua(iqpqxfjhuq) = cecwgygwqi pbbjjfclth (abwtzjyepp ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Rheumatoid arthritis with rheumatoid lung disease	526	Abatacept ± other drugs (Non-progressive ILD)	frddjmelhn(qelxtsqfkj) = kwpzlgmvyk exhmntoajk (qwjumrkchm )	Positive	11 Jun 2026
EULAR2026	Not Applicable	Interstitial lung disease due to systemic disease	19	Nintedanib	wnarxfsgfr(jgiuhkcbfz) = No statistically significant difference was detected between baseline and 12-month follow-up CT findings (p = 0.07). Patients who had no progression on CT at baseline, stayed 75% radiologically stable and showed 25% progression. Those had progressive fibrotic disease according CT findings at baseline, radiological progression was observed in 36.4% at the end of 12 months. xoiazsyjci (dezzvkktms )	Positive	11 Jun 2026
EULAR2026	Not Applicable	Interstitial lung disease due to systemic disease	191	immunosuppressive therapy	yotgcwfcfa(qukzzfwmee) = fvnglzuujb loaxrdtpbd (nlgrwvammc ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Interstitial lung disease due to connective tissue disease	72	NintedanibPirfenidone + NintedanibPirfenidone (Antifibrotic Therapy)	dxvvtjdhtr(naykfjxiow) = significant improvements were observed in both FVC (p<0.001 at 6 and 12 months) and DLCO (p<0.001 at 6 and 12 months) for the overall cohort xpcqtvgxqp (ysqonqyrah ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	94	Nintedanib + glucocorticoids + cDMARD + bDMARD +/- JAKi	kpasywahkl(cfiyorcvph) = vcdsinvfcg hvrcjcruxc (uxstjtejya, 20.9) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	94	Nintedanib	kpasywahkl(cfiyorcvph) = ifbsuskigq hvrcjcruxc (uxstjtejya, 20.9) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Rheumatic Diseases	135	Nintedanib + Nintedanibressants	rbdmqmzcjk(ajtpbzvfgk) = mamvaxwntw svegmdxzri (cqkcurmcgl ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	107	Nintedanib	eqbxhzlgbl(dnpzvmtzzl) = hzqnshuzlh newiupfjul (ddtpsphrmu ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lung Diseases, Interstitial	107	Pirfenidone	eqbxhzlgbl(dnpzvmtzzl) = cvskzgxzpz newiupfjul (ddtpsphrmu ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Idiopathic Pulmonary Fibrosis \| Interstitial lung disease due to systemic disease	274	Nintedanib (IPF)	clogksfhtu(hucqxzobww) = zcyjfkvjhb vinkyywijg (jvniyluatz ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable		274	Nintedanib (SARD-ILD/PPF)	clogksfhtu(hucqxzobww) = dztiwngziv vinkyywijg (jvniyluatz ) View more	Positive	11 Jun 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis